Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

This study has been terminated.

(Sponsor decision)

Sponsor:

Information provided by (Responsible Party):

Amgen

ClinicalTrials.gov Identifier:

NCT01708629

First received: September 21, 2012

Last updated: November 20, 2015

Last verified: November 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	October 2015
Primary Completion Date:	August 2014 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	April 14, 2015